Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
about
Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studiesPotential increased risk of cancer from commonly used medications: an umbrella review of meta-analysesEvaluating the impact of database heterogeneity on observational study resultsAssessment of vibration of effects due to model specification can demonstrate the instability of observational associationsCharacterizing treatment pathways at scale using the OHDSI networkGathering and exploring scientific knowledge in pharmacovigilanceToward high-throughput phenotyping: unbiased automated feature extraction and selection from knowledge sourcesComputational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworkspSCANNER: patient-centered Scalable National Network for Effectiveness ResearchA pipeline to extract drug-adverse event pairs from multiple data sourcesPharmacovigilance Using Clinical NotesCaveats for the use of operational electronic health record data in comparative effectiveness research.Evaluating performance of risk identification methods through a large-scale simulation of observational data.Signal detection and monitoring based on longitudinal healthcare dataDrug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic.Toward enhanced pharmacovigilance using patient-generated data on the internetUsing real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.Feasibility and utility of applications of the common data model to multiple, disparate observational health databases.Sustainability considerations for health research and analytic data infrastructures.A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions.Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies.Drug-induced adverse events prediction with the LINCS L1000 dataMedication-wide association studies.Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest.Similarity-based modeling applied to signal detection in pharmacovigilance.Ongoing challenges in pharmacovigilance.Evaluation of matched control algorithms in EHR-based phenotyping studies: a case study of inflammatory bowel disease comorbiditiesStructured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement networkSystems pharmacology augments drug safety surveillanceDetecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series.A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.A Mixture Dose-Response Model for Identifying High-Dimensional Drug Interaction Effects on Myopathy Using Electronic Medical Record DatabasesGraphic Mining of High-Order Drug Interactions and Their Directional Effects on Myopathy Using Electronic Medical Records.The potential of translational bioinformatics approaches for pharmacology research.Ethics and Epistemology in Big Data Research.Comparing Propensity Score Methods for Creating Comparable Cohorts of Chiropractic Users and Nonusers in Older, Multiply Comorbid Medicare Patients With Chronic Low Back PainSystems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Good Signal Detection Practices: Evidence from IMI PROTECTA method for systematic discovery of adverse drug events from clinical notes
P2860
Q24288975-AD139DC7-CC67-4D48-BD08-77E36ECD3CD9Q24289205-8E23B943-3745-46F2-AE50-5023E2B1DB2CQ24289210-83AAA5BB-6547-4A5E-A135-D9B0840170A7Q24289437-76EA19FF-E205-4396-B94E-7C66727A78B1Q27320806-44ACA50B-ECFE-4CA5-8144-C9D3D5C1A7ADQ28536855-0C7DE835-02DF-4688-BA3B-65DA8295A9EAQ28597791-0874A9C4-FAD6-4C49-9753-069BEAF9A2FBQ28651547-B34EE1A2-02E1-4A5B-8E6B-78B7EFF475E4Q28656420-D1880948-2A5E-482B-98D6-D180C75D7F83Q28658495-ED6EA3D8-52AF-48C0-9A6D-5D1F1A741FDDQ30058397-026496A0-6FF3-4F66-989D-B488CA545869Q30649696-B8623542-D69E-42EE-8594-9E83CE360F6EQ30685309-3725494B-C171-4F08-BB1C-707E4D35F434Q30706851-11F1BB9A-8A81-4693-84DB-B9D107856B93Q30706858-3A1DDD6D-68EF-46C3-B612-C77F85DB511AQ30796597-161EAE63-32A5-412A-95FF-2D640CFFFAD3Q30875888-6764BB6F-1EF8-434E-A35E-AE82CFCD46C6Q30876081-2CCABD76-194A-4052-A4A0-51A8FA011265Q30891288-B3D7DAC2-1254-4E2B-81CE-BB7202E700A6Q30925458-42BF2243-0A43-427D-AAAA-3FEE31C5983AQ30979182-546C0DDE-8BD1-4711-897C-4043A40FD4B9Q31063299-5621144F-F7BB-4CE8-8E48-537A460ABB5AQ31092242-8F817ECA-6DA9-4FAF-845F-8AD155423961Q33633627-BD3D15D4-881D-4CF7-8F88-FDC3580753F1Q34051886-B4C60420-54B9-432C-B582-663585FD502CQ34413023-6121B2D8-10F8-4B0B-A376-C3DFE31ACA26Q34417013-5731FFE7-7686-4C65-A20E-AFBC7F4BA9A2Q34663931-77CB7C7D-C7B7-4C40-931C-0836452DDE66Q34996701-CD1C19B9-E3B5-46F6-9474-135745D67FD1Q35075939-95A21259-B0D5-4580-B232-B2EBCB227A19Q35135876-8C9BC402-96E7-4E26-A57F-31F6BE6584FAQ35657554-F9BEE36D-B6B7-43A0-9E73-BC87D2A2F2FBQ36034963-26E972E1-DDE9-411C-B99B-EC875323FCA4Q36034970-C6FCD6D5-C81B-4A76-B960-06AF6C5251EDQ36125546-4A2BFC7E-387E-4E2A-8986-A827396C6127Q36315748-9CF1990E-8634-43FF-894B-316560B988A2Q36396017-FA13513F-35D6-4F12-A6E3-F66238B68A6DQ36599215-16AFF5B7-DCA9-4C05-B975-E40CC9FCFE22Q36914069-C2B3FB2E-258C-4758-A530-564F3B9AEA8DQ37040215-90179852-7EE7-4338-B732-A01FEA92B5D3
P2860
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Empirical assessment of method ...... Medical Outcomes Partnership.
@ast
Empirical assessment of method ...... Medical Outcomes Partnership.
@en
type
label
Empirical assessment of method ...... Medical Outcomes Partnership.
@ast
Empirical assessment of method ...... Medical Outcomes Partnership.
@en
prefLabel
Empirical assessment of method ...... Medical Outcomes Partnership.
@ast
Empirical assessment of method ...... Medical Outcomes Partnership.
@en
P2093
P2860
P356
P1476
Empirical assessment of method ...... Medical Outcomes Partnership.
@en
P2093
Abraham G Hartzema
J Marc Overhage
Judith A Racoosin
Patrick B Ryan
Paul E Stang
P2860
P304
P356
10.1002/SIM.5620
P407
P577
2012-09-27T00:00:00Z